Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine
Neutralization and binding antibody response to second bivalent COVID-19 vaccination in nursing home residents
Delivery platforms for broadly neutralizing antibodies
Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers
Generation and characterization of infectious molecular clones of transmitted/founder HIV-1 subtype C viruses
Diagnostic TR-FRET assays for detection of antibodies in patient samples
Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare Workers
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022
Brief Report: Declining Rates of SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies
COVID-19 booster dose induces robust antibody response in pregnant, lactating, and nonpregnant women
Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design
Maternally transferred mAbs protect neonatal mice from HSV-induced mortality and morbidity
Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination
Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization
Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice
SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children
COVID-19 booster dose induces robust antibody response in pregnant, lactating, and nonpregnant women
Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms
Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency
COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
Humanized mice reveal a macrophage-enriched gene signature defining human lung tissue protection during SARS-CoV-2 infection
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines
Durability and Cross-Ractivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children
Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motif
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
Multi-modal profiling of human fetal liver-derived hematopoetic stem cells reveals the molecular signature of engraftment potential
Poly I:C and STING agonist-primed DC increase lymphoid tissue polyfunctional HIV-1-specific CD8+ T cells and limit CD4+ T-cell loss in BLT mice
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS- CoV-2 Omicron variant
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy
Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain
Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Naive Nursing Home Residents
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis
Innate immune reconstitution in humanized bone marrow-liver-thymus (HuBLT) mice governs adaptive cellular immune function and responses to HIV-1 infection
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Multiple circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
T cell-tropic HIV efficiently infects alveolar macrophages through contact with infected CD4+T cells.
The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells
Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention
COVID-19 neutralizing antibodies predict disease severity and survival
Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
SARS-CoV-2-specific ELISA development
Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays
Spontaneous Glycan Reattachment Following N-Glycanase Treatment of Influenza and HIV Vaccine Antigens.
Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids.
AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region.
Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge.
Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
Multilineage transduction of resident lung cells in vivo by AAV2/8 for alpha1-antitrypsin gene therapy.
Insulin-like growth factor 2 modulates murine hematopoietic stem cell maintenance through upregulation of p57.
Improvements and Limitations of Humanized Mouse Models for HIV Research.
Engineering humoral immunity as prophylaxis or therapy.
Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.
Vectored antibody gene delivery for the prevention or treatment of HIV infection.
Broadly neutralizing antibodies abrogate established hepatitis C virus infection.
Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice.
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission.
Broad protection against influenza infection by vectored immunoprophylaxis in mice.
Antibody gene transfer for HIV immunoprophylaxis.
Antibody based protection against HIV infection by Vectored Immunoprophylaxis.
Faculty of 1000 Evaluation
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.
Faculty of 1000 Evaluation
Dimeric 2G12 as a potent protection against HIV-1.
MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output.
Lentiviral vector delivery of human interleukin-7 (hIL-7) to human immune system (HIS) mice expands T lymphocyte populations.
Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome.
Endothelial Protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow.
Nitric oxide is a regulator of hematopoietic stem cell activity.
Viscoelastic properties of demineralized human dentin measured in water with atomic force microscope (AFM)-based indentation.